Sequana Medical said today that it added $9.3 million to the $26 million Series C round it raised last year, as it readies for a U.S. clinical trial of its Alfapump implantable pump.
Zurich-based Sequana said existing backers NeoMed Management, VI Partners, Biomed Invest, Capricorn Health-tech Fund, Entrepreneurs Fund and Life Science Partners put up $5.5 million. New investors Salus Partners and Quest for Growth put in another $3.8 million, the company said.
Sequana won CE Mark approval in the European Union in 2011 for the Alfapump, a fully implantable pump designed to continuously remove excess abdominal fluid in patients suffering from liver disease. Today the company said it plans to use the proceeds from the Series C extension to expand the CE Mark indication for heart disease and pursue U.S. approval.
“This latest financing represents an important next step for Sequana Medical and we thank both our current investors as well as new participants, Salus Partners and Quest for Growth, for their endorsement of the Company’s potential,” CEO Noel Johnson said in prepared remarks. “While revenues generated from sales of Sequana Medical’s Alfapump system, indicated for patients with late-stage liver disease and certain cancers, are being reinvested into further expansion in CE-Mark territories, the funds raised from the Series C extension round will allow us to expedite planned clinical trials in th…
Publication date: Available online 11 August 2018Source: Pathology – Research and PracticeAuthor(s): Yuanyuan Shang, Fang Zhang, Dehui Li, Chang Li, Hongbo Li, Yingjian Jiang, Dianliang ZhangAbstractUbiquinol-cytochrome c reductase complex core protein 2 (UQCRC2) is an important subunit of mitochondrial respiratory complex III. However, its role in tumorigenesis and tumor progression remains unknown, especially with regards to colorectal cancer (CRC). In this research, we measured the expression of UQCRC2 protein by immunohistochemistry assay in 89 paired paraffin-embedded tumor tissues and corresponding adjacent normal ti…
Publication date: Available online 9 June 2018Source: Journal of Minimally Invasive GynecologyAuthor(s): Dimitrios Nasioudis, Evelyn Minis, Eloise Chapman-Davis, Melissa K. Frey, Thomas A. Caputo, Steven S. Witkin, Kevin HolcombAbstractStudy ObjectiveEvaluate the prevalence, trends, and outcomes of minimally invasive surgical (MIS) staging of malignant ovarian germ cell tumors (MOGCTs) apparently confined to the ovary.DesignRetrospective cohort study (Canadian Task Force classification II-2).SettingParticipating hospitals in the National Cancer Data Base.PatientsWomen diagnosed between 2010 and 2014 with a MOGCT apparently…
Publication date: Available online 11 August 2018Source: Gynecologic Oncology ReportsAuthor(s): Mackenzie W. Sullivan, Susan C. Modesitt
“Is CT Scan more Accurate than Endoscopy in Identifying Distance from the Anal Verge for Left Sided Colon Cancer? A Comparative Cohort Analysis”.
J Invest Surg. 2018 Aug 08;:1-8
Authors: Costi R, Ricco’ M, Negrini G, Wind P, Violi V, Le Bian AZ
PURPOSES: Accurately localizing colorectal cancer during surgery may be challenging due to intraoperative limitations. In the present study, localization of left-sided colon cancer (LCC) by CT scan is compared to colonoscopy.
MATERIAL AND METHODS: Consecutive patients with LCC located by colonoscopy and CT scan and undergoing left-hemicole…
The sessions are run in a bid to help women boost their self-confidence as they fight against cancer.
Authors: Sacco PC, Maione P, Palazzolo G, Gridelli C
INTRODUCTION: Lung cancer is predominantly a disease that affects the elderly; about 30-40% of lung cancers are diagnosed in patients aged 70 or more. The increasing number of elderly patients over the next decades is generating a new social and health problem; despite that, these patients are under-represented in clinical trials and under-treated in clinical practice. Areas covered: The main difficulty in treating elderly patients is to maximize the therapy benefits while minimizing the treatment risk. Elderly patients show a vulnerable clinical profile…
Publication date: Available online 11 August 2018Source: British Journal of Oral and Maxillofacial SurgeryAuthor(s): S. Lahtinen, P. Koivunen, T. Ala-Kokko, O. Kaarela, P. Ohtonen, P. Laurila, J.H. LiisananttiAbstractWe retrospectively studied 136 patients who had free flap reconstruction for cancer of the head and neck at a single centre (2008–2015) to evaluate complications, assess factors associated with them, and analyse their impact on outcome. Preoperative and perioperative data, and surgical and medical complications were recorded, and the impact of the complications on duration of hospital stay and survival w…
ConclusionThis study confirmed the role of FABP-4 in pathogenesis of type 2 diabetes &breast cancer via enhancing angiogenesis, inflammatory and epigenetic instability biomarkers.
Authors: Wright F, Hapgood G, Loganathan A, Dunn N, Philpot S, Moore J, Mollee P
OBJECTIVE: To evaluate relative survival of patients in Queensland with different lymphoma subtypes; to determine whether outcomes have improved with recent changes in treatment; to evaluate relative survival according to place of residence and socio-economic status.
DESIGN: Retrospective population-based study; analysis of data from the Oncology Analysis System, an online reporting tool for cancer incidence and outcomes in Queensland.
PARTICIPANTS: Patients over 15 years of age diagnosed with lymphoma in Queensland du…
Authors: Shasttiri A, Rostamian Delavar M, Baghi M, Dehghani Ashkezari M, Ghaedi K
PMID: 30092718 [PubMed – as supplied by publisher]